Search results

This guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over. It aims to improve care for people with non-Hodgkin's lymphoma by promoting the best tests for diagnosis and staging and the most effective treatments for 6 of the subtypes. Tests and treatments covered include excision biopsy, radiotherapy, immunochemotherapy and stem cell transplantation.

Result type

NICE guideline

Published

20 July 2016

Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults.

Result type

Technology appraisal guidance

Published

21 March 2018

Evidence-based recommendations on lenalidomide (Revlimid) with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults.

Result type

Technology appraisal guidance

Published

7 April 2020

Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies.

Result type

Technology appraisal guidance

Published

28 February 2023

Evidence-based recommendations on zanubrutinib for treating relapsed or refractory mantle cell lymphoma in adults who have had 1 line of treatment only.

Result type

Technology appraisal guidance

Published

10 July 2025

Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for relapsed or refractory follicular lymphoma in adults.

Result type

Technology appraisal guidance

Published

7 June 2023

Evidence-based recommendations on ibrutinib (Imbruvica) for treating relapsed or refractory mantle cell lymphoma in adults.

Result type

Technology appraisal guidance

Published

31 January 2018

Evidence-based recommendations on bortezomib (Velcade) for untreated mantle cell lymphoma in adults.

Result type

Technology appraisal guidance

Published

16 December 2015

Evidence-based recommendations on rituximab for the first-line treatment of stage III–IV follicular lymphoma.

Result type

Technology appraisal guidance

Published

25 January 2012

Evidence-based recommendations on brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma in adults who have previously had a Bruton’s tyrosine kinase (BTK) inhibitor.

Result type

Technology appraisal guidance

Published

24 February 2021

Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months after treatment with rituximab or a rituximab-containing regimen in adults.

Result type

Technology appraisal guidance

Published

13 May 2020

Evidence-based recommendations on mosunetuzumab (Lunsumio) for relapsed or refractory follicular lymphoma in adults.

Result type

Technology appraisal guidance

Published

31 May 2023

Evidence-based recommendations on rituximab (MabThera) for the maintenance treatment of follicular non-Hodgkin’s lymphoma in adults.

Result type

Technology appraisal guidance

Published

22 June 2011

Topic prioritisation

Result type

Technology appraisal guidance

Status

Topic prioritisation

Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults.

Result type

Technology appraisal guidance

Published

2 October 2019